Moreover, STING agonists have exhibited potent anti‐tumor activity in various cancer types (Fang et al. 2023; Yin et al. 2022) and have been shown to overcome drug resistance (Nakamura et al. 2021; Huang et al. 2021). The gene discussed is STING1; the disease is neoplasm.